TITLE

Adverse Endocrine and Metabolic Effects of Psychotropic Drugs: Selective Clinical Review

AUTHOR(S)
Bhuvaneswar, Chaya G.; Baldessarini, Ross J.; Harsh, Veronica L.; Alpert, Jonathan F.
PUB. DATE
December 2009
SOURCE
CNS Drugs;2009, Vol. 23 Issue 12, p1003
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article critically reviews selected, clinically significant, adverse endocrine and metabolic effects associated with psychotropic drug treatments, including hyperprolactinaemia, hyponatraemia, diabetes insipidus, hypothyroidism, hyperparathyroidism, sexual dysfunction and virilization weight loss, weight gain and metabolic syndrome (type 2 diabetes mellitus, dyslipidaemia and hypertension). Such effects are prevalent and complex, but can be managed clinically when recognized. They encourage continued critical assessment of benefits versus risks of psychotropic drugs and underscore the importance of close coordination of psychiatric and general medical care to improve long-term health of psychiatric patients. Options for management of hyperprolactinaemia include lowering doses, switching to agents such as aripiprazole, clozapine or quetiapine, managing associated osteoporosis, carefully considering the use of dopamine receptor agonists and ruling out stress, oral contraceptive use and hypothyroidism as contributing factors. Disorders of water homeostasis may include syndrome of inappropriate antidiuretic hormone (SIADH), managed by water restriction or slow replacement by hypertonic saline along with drug discontinuation. Safe management of diabetes insipidus, commonly associated with lithium, involves switching mood stabilizer and consideration of potassium-sparing diuretics. Clinical hypothyroidism may be a more useful marker than absolute cut-offs of hormone values, and may be associated with quetiapine, antidepressant and lithium use, and managed by thyroxine replacement. Hyper-parathyroidism requires comprehensive medical evaluation for occult tumours. Hypocalcaemia, along with multiple other psychiatric and medical causes, may result in decreased bone density and require evaluation and management. Strategies for reducing sexual dysfunction with psychotropics remain largely unsatisfactory. Finally, management strategies for obesity and metabolic syndrome are reviewed in light of the recent expert guidelines, including risk assessment and treatments, such as monoamine transport inhibitors, anticonvulsants and cannabinoid receptor antagonists, as well as lifestyle changes.
ACCESSION #
47994961

 

Related Articles

  • Female Sexual Dysfunction: Potential for Pharmacotherapy. Fourcroy, Jean L. // Drugs;2003, Vol. 63 Issue 14, p1445 

    The act of sex includes a woman’s sexual self and self-image, intimate relationships, family, society and culture. The complexities of her environment, sexual and partner history, past relationships, mental health status, current medical problems and hormonal status all play a role. An...

  • Salvage of sildenafil failures with cabergoline: a randomized, double-blind, placebo-controlled study. Safarinejad, M. R. // International Journal of Impotence Research;Nov/Dec2006, Vol. 18 Issue 6, p550 

    To evaluate the safety and efficacy of cabergoline in men with erectile dysfunction (ED) who did not respond to sildenafil. Four hundred two sildenafil nonresponders aged from 21 to 59 years were included in the study. Patients were randomly divided into group 1, those who received 0.5–1...

  • Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients. Harting, Matthew T.; Lally, Kevin P.; Andrassy, Richard J.; Vaporciyan, Ara A.; Cox, Jr., Charles S.; Hayes-Jordan, Andrea; Blakely, Martin L. // Journal of Cancer Research & Clinical Oncology;Apr2010, Vol. 136 Issue 4, p561 

    It is unclear whether age at diagnosis is an important prognostic factor in patients with osteosarcoma. Understanding this relationship could yield valuable insight into therapeutic rationale, focus patient selection for clinical trials, advance molecular concepts and theories, and expand...

  • Surgery after Neoadjuvant Chemotherapy for Locally Advanced Extrapulmonary Poorly Differentiated Neuroendocrine Cancer. Lessing, Yonatan; Ben-Haim, Menahem; Lahat, Guy; Nackache, Richard; Klausner, Joseph M.; Shmueli, Einat; Lubezky, Nir // American Surgeon;Aug2011, Vol. 77 Issue 8, p1102 

    The article describes several cases of patients with neuroendocrine tumors (NET) who were treated with neoadjuvant chemotherapy consisting of etoposide and cisplatinum after surgery. A gastroscopic examination performed in one patient showed poorly differentiated neuroendocrine carcinoma. The...

  • Foxp3+ cell infiltration and granzyme B+/Foxp3+ cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma. Pölcher, Martin; Braun, Michael; Friedrichs, Nicolaus; Rudlowski, Christian; Bercht, Eva; Fimmers, Rolf; Sauerwald, Axel; Keyver-Paik, Mignon-Denise; Kübler, Kirsten; B#x00FC;ttner, Reinhard; Kuhn, Walther C.; Hernando, Juan-José // Cancer Immunology, Immunotherapy;Jun2010, Vol. 59 Issue 6, p909 

    Preoperative neoadjuvant chemotherapy (NAC) can significantly reduce tumour burden in patients with primarily unresectable chemosensitive tumours, allowing a more complete cytoreduction during debulking surgery and facilitating evaluation of tumour chemosensitivity, identification of appropriate...

  • Oropharyngeal carcinoma and its treatment in Finland between 1995–1999: a nationwide study. Mäkitie, Antti A.; Pukkila, Matti; Laranne, Jussi; Pulkkinen, Jaakko; Vuola, Jyrki; Bäck, Leif; Koivunen, Petri; Grénman, Reidar // European Archives of Oto-Rhino-Laryngology;Feb2006, Vol. 263 Issue 2, p139 

    The survival figures for advanced stage oropharyngeal carcinoma (OPC) have remained moderate in spite of radical combined modality treatments. The purpose of this study was to investigate the used treatment approach and the outcome of OPC in a nationwide study. Retrospective clinicopathological...

  • Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Vandenput, I.; Van Calster, B.; Capoen, A.; Leunen, K.; Berteloot, P.; Neven, P.; Moerman, Ph.; Vergote, I.; Amant, F. // British Journal of Cancer;7/21/2009, Vol. 101 Issue 2, p244 

    Background:To investigate the value of neoadjuvant chemotherapy (NACT), followed by interval debulking surgery (IDS), in endometrial cancer with transperitoneal spread (stage IV).Methods:Patients with endometrial cancer with transperitoneal spread, as determined by laparoscopy (±pleural...

  • Primary adrenocortical sarcomatoid carcinoma: case report and review of literature. Nabila Moulai; Marie-Hélène Laverrière; Olivier Chabre; Jean-Luc Descotes; Elisabeth Brambilla // Virchows Archiv;Feb2008, Vol. 452 Issue 2, p215 

    Abstract  Adrenocortical carcinoma (AC) mixed with a sarcoma or sarcoma-like component is exceptional, and only six cases have been detailed in the literature, three including osteo-, chondro-, or rhabdomyosarcoma components, and three others only showing a malignant spindle cell...

  • Between Scylla and Charybdis: antipsychotic and other psychotropic medications in older nursing home residents. Pollock, Bruce G.; Mulsant, Benoit H. // CMAJ: Canadian Medical Association Journal;4/19/2011, Vol. 183 Issue 7, p778 

    In this article the authors discusses aspects of the risks involved in the use of psychotropic medications in old nursing home patients afflicted with dementia. They say that psychotropic drugs, like risperidone and citalopram, may increase mortality risks of older patients and the risk-benefit...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics